Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung12: Adjuvant Dato-DXd + Rilvegostomig in Stage I NSCLC
NCT06564844Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Countries
- 10
01
Overview
A Phase 3 trial of datopotamab deruxtecan, rilvegostomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2024; status: active, not recruiting.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06564844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564844.